ReviewJournal of the European Academy of Dermatology and Venereology : JEADV2020
Active implications for dermatologists in 'SARS-CoV-2 ERA': Personal experience and review of literature.
Review in Journal of the European Academy of Dermatology and Venereology : JEADV, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate.Pharmaceutics · 2022Review
- Coronavirus disease 2019 and pityriasis rosea: A review of the immunological connection.The Journal of dermatology · 2022Review
- Adverse skin reactions to personal protective equipment during COVID-19 pandemic in Italian health care workers.Dermatologic therapy · 2022Article
- Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities.Journal of clinical medicine · 2022Review
- Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy.Dermatology and therapy · 2021Review
- How to fight SARS-COV-2 vaccine hesitancy in patients suffering from chronic and immune-mediated skin disease: four general rules.Human vaccines & immunotherapeutics · 2021Article
- Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Article
- Management of patients with pemphigus vulgaris during the COVID-19 pandemic: Experience of a second level dermatology center.The Australasian journal of dermatology · 2021Article
- Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience.Dermatologic therapy · 2021Article
- Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association.Journal of medical virology · 2021Article
- Skin involvement in SARS-CoV-2 infection: Case series.Journal of medical virology · 2020Article
- Time to restart: protocol of resumption of activities of a dermatological clinic of a level II hospital in the COVID-19 era.International journal of dermatology · 2020Article
- Global coronavirus pandemic (SARS-CoV-2): Past, present, and future of pediatric dermatology.Dermatologic therapy · 2020Article
- The skin in the era of coronavirus pandemic.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020Article
- COVID-19 era: A chance to learn something new about monitoring psoriatic patients in biological therapy.Dermatologic therapy · 2020Article
- How can I take care of you? The dermatologist meets patients' needs during the COVID-19 pandemic.Dermatologic therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.